Agilent/Dako

MutS Protein Homolog 6 (Autostainer Link 48)

#IR086 · western blot

17
Citing papers
366
Combined citations
Supplier page Find this product

Research areas

Genetic factors in colorectal cancer9Cancer Genomics and Diagnostics5Colorectal Cancer Treatments and Studies5Cancer Immunotherapy and Biomarkers4Colorectal Cancer Screening and Detection3Cancer Cells and Metastasis3Cholangiocarcinoma and Gallbladder Cancer Studies2Colorectal and Anal Carcinomas2

Papers citing this product

1
“Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”
Journal of Experimental & Clinical Cancer Research·2023·86 cit.·DOI
2
Advantage of <i>HSP110</i> (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients
Oncotarget·2018·46 cit.·DOI
3
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma
BMC Medicine·2024·41 cit.·DOI
4
Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression
Modern Pathology·2018·41 cit.·DOI
5
PD‑L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study
Oncology Letters·2021·40 cit.·DOI
6
Clinical Performance of the Idylla MSI Test for a Rapid Assessment of the DNA Microsatellite Status in Human Colorectal Cancer
Journal of Molecular Diagnostics·2019·36 cit.·DOI
7
Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial
Journal of Clinical Pathology·2015·26 cit.·DOI
8
A Prospective Study on the Roles of the Lymphocyte-to-Monocyte Ratio (LMR), Neutrophil-to-Lymphocyte Ratio (NLR), and Platelet-to-Lymphocyte Ratio (PLR) in Patients with Locally Advanced Rectal Cancer
Biomedicines·2023·13 cit.·DOI
9
FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing
Journal of Clinical Pathology·2022·10 cit.·DOI
10
Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system
Journal of Cancer Research and Clinical Oncology·2020·9 cit.·DOI